Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma
Weijing Sun(Huazhong Agricultural University), Kim M. Olthoff(University of Pennsylvania), Daniel G. Haller(American Society of Clinical Oncology), Peter J. O’Dwyer(University of Pennsylvania), K. Rajender Reddy(University of Pennsylvania Health System), Michael C. Soulen(University of Pennsylvania), Ursina Teitelbaum(University of Pennsylvania), Davendra Sohal(University of Cincinnati), Bruce J. Giantonio(Massachusetts General Hospital), Kristine Mykulowycz(University of Pennsylvania), Abraham Shaked(University of Pennsylvania), Mark Rosen(California University of Pennsylvania), Millie Caparro(University of Pennsylvania)
Cited by 97
Related Papers
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k